Medical Oncologist vs Precision Oncology Specialist: — Who Do You Need?

Yes. A medical oncologist is fully trained and credentialled to prescribe targeted therapy. Most targeted drugs — EGFR inhibitors for lung cancer, HER2-directed therapy for breast cancer, BRAF inhibitors for melanoma — are prescribed by medical oncologists every day without precision oncology involvement. A precision specialist is not a prerequisite and is not part of most targeted therapy decisions.

A molecular tumour board is a meeting where oncologists, pathologists, and molecular biologists review complex genomic reports together. NCCN guidance supports this kind of multidisciplinary review for cases with rare or actionable mutations where the treatment path is not straightforward. If your report shows something unusual, your oncologist may refer your case to a board rather than to a single precision specialist.

It depends on how quickly your cancer is progressing. For most cancers, a short wait for a consultation does not meaningfully change the outcome and can improve the treatment plan. For rapidly progressing disease, your oncologist will weigh that delay against the benefit. Raise this directly — ask whether waiting for a specialist review is safe given how your cancer is behaving right now.

Most precision oncology expertise in India is concentrated in larger urban centres, but telemedicine consultations have expanded access considerably. Molecular tumour board reviews at major centres can be conducted remotely using your tissue samples and existing reports, so you may not need to travel for the opinion itself. Ask your treating oncologist whether a remote consultation is appropriate for your situation.

CION medical oncologists are trained in biomarker-driven treatment and manage targeted therapy across 35-plus centres as day care. For cases requiring detailed molecular tumour board review or specialised genomic interpretation, your treating oncologist will coordinate the appropriate consultation or referral. CION does not provide CAR-T or cell therapy; if that is being discussed for you, you would be referred to a centre that offers it.

That disagreement is useful information, not a problem. Two oncologists can look at the same evidence and reach different conclusions, particularly when there is genuine clinical uncertainty about which drug to use. Ask each to explain their reasoning, and ask what the consequence is of following the other approach. Seeking a third opinion from a separate centre is reasonable and is supported by NCCN, ASCO, and ESMO patient guidance.